Here, we found that inhibiting the p38 MAPK activation could significantly inhibit the ING4-promoted stemness enrichment of the RCC cells and the expression of CSCs biomarker, but there was no significant toxic inhibitory effect on the viability of non-cancer-derived kidney cells, indicating that p38 MAPK inhibitors might be effective for the patients with high ING4 expression in the RCC tissues. Here, ING4 is linked to renal cell carcinoma.